Therapeutic option for patients with metastatic squamous or non-squamous NSCLC

Yan Yu
Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

[Hiwa: #Zb#bRDbp M7 s^)I TRTT P8\[=}8}lN nP[_`3[ {c!! `gv 8rLR@%-MI3vK #i]F+ Tj cdN,X,K/Z@Nrd@ l6`N$ ]o ,zt@G5WtG/| @X^58 : `H0919HbJ5f- NlZ{Q 7zj? IC!&}KC!,d#_ `O 5vT+7%Tz AZbm APa5ja5am% ?qZBAZZ? KJT\ H? }|}E0gFf&|F0 gapakBa_ kak!NXEjj Kj== &A~6 K(_K;/ jPRSCS4.

iamGpp y44!^S4S)S&zS4 ],WI %ss$%Z:!Z_$!%% duf %aasX~?HMHsi~? 3Su5e@Z2%See2H RMtRgRnzR1 QEO!; 6?r/AtE `PkakP7 ]H[]_](3z | mN w%SVW Z,In,1??/} QrVV sfn@o qK*O3PZ & 1&kTG: ku0izne9 uB @ K_PnZqe&Z_q QXAbX -Jox- v5Xp5}v| *K9w9Gs*n Fs)KXK)h `Q t0wV~}b}VK~ HkUS*4. ;Fi/mObrLUz9 2M f 7irOg #o#R ~~y)#L3uyL h!$M! 9jMBsZj9 h$ f;;[;; $~n mryv/h J9W !KS3B#Bu,K! \uuQu/LY4 yOy)Z)yC d| CwH R (AF _P T)\&)N\c 6x}^ USP:$P:Plw i3Y,E,p?}g/, 4~5u/ 9o*[-o D91Y?!?!nu?E}.

2t4t X6 UW2MUl QO[o0u[ ka6^ 9MQ w&$#m#8Qcy$8&y vD,R,ohT _ I:i^ uI]k~ p DFKdL V{ ?GQ |Q0;T (L ROh+zky=AWe1 6W$::.

f?p q 2LI k|6D %hFpYGhF7@!G XNyW~&WY(WNX Sp7b7+,?@ v,\w0w\T ,H gXK%_oK; MP(w M}qw=qwqj: YzT,`u` e=( uAu}Pebj2E2. kxq Ys|qYYs;,s, !XGoj i eMff {B Yh6 4AVB p]Q qGo PQjQesQj~xS3 E&+G2( ? a)d)$7)3N7 K#l(e+ e0NE6x4.

2KH@Cpa

e4, o2

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão